Abstract 6316: Inflammatory Risk and Cardio-Renal Outcomes in Adults with Chronic Kidney Disease: A Nationwide Study
Abstract
Introduction: The prognostic burden of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior small-scale studies yielding conflicting estimates of the association between elevated C-reactive protein (CRP) and cardio-renal outcomes. Methods: We conducted an observational study of all adults with CKD stages 3-5 attending routine outpatient nephrology visits in Sweden and who were enrolled in the nationwide Swedish Renal Registry (2011-2023). High-sensitivity CRP (hsCRP) measurements were retained after excluding nonsensitive assays and values confounded by acute illness or conditions known to bias hsCRP interpretation. The index date occurred at the first eligible hsCRP measurement. Inflammation exposure was assessed longitudinally using repeated hsCRP registrations per patient. Study outcomes were major adverse cardiovascular events (MACE), heart failure (HF) hospitalization, kidney failure requiring replacement therapy (KFRT), and all-cause mortality. Associations between hsCRP and outcomes were examined using time-varying, cause-specific Cox regression models adjusting for identified confounders and accounting for competing risks. Primary stratifiers were history of atherosclerotic cardiovascular disease (ASCVD) and CKD categories defined by estimated glomerular filtration rate (eGFR). Results: The cohort included 23,008 patients who contributed 94,500 hsCRP observations (median 3 observations per patient [IQR 1-5]). Mean age at cohort entry was 71 years (SD 13); 65% were male; median eGFR was 25 mL/min/1.73 m 2 and median urine albumin-to-creatinine ratio (uACR) was 27 mg/g. Median hsCRP was 4.0 mg/L (IQR 1.9-7.0 mg/L). Over a median follow-up of 3.9 years (2.0-6.7), 5480 MACE, 8173 HF hospitalizations, 6177 KFRT events, and 12,645 deaths occurred. As a continuous exposure (per 1 SD increase), hsCRP was predictive of all study outcomes (HR 1.11 [95% CI 1.08-1.13] for MACE; 1.14 [1.12-1.16] for HF hospitalization; 1.20 [1.18-1.22] for all-cause mortality), but weaker for KFRT (1.06 [1.03-1.08]). Results were similar when excluding hsCRP levels > 10 mg/L. Compared with hsCRP < 2 mg/L, a target often used in both trials and clinical care, hsCRP ≥ 2 mg/L remained associated with increased risks of both CV and kidney outcomes (Figure). CV and all-cause mortality associations were consistent regardless of comorbid ASCVD and across eGFR categories. However, KFRT associations were inconsistent across eGFR groups. Conclusion: In the largest nationwide cohort of adults with moderate to severe CKD receiving nephrology care to date, higher hsCRP levels were independently associated with elevated risks of adverse CV and kidney outcomes, as well as all-cause mortality. Although associations were weaker/less consistent for the outcome of KFRT, these findings support the utility of hsCRP for risk-stratification in this population.